Sanofi Appoints Belén Garijo as New CEO, Replacing Paul Hudson

Sanofi has announced the departure of its CEO, Paul Hudson, effective immediately. The company’s board of directors has appointed Belén Garijo, currently the CEO of Merck KGgA, as Hudson’s successor, with her official start date set for April 29, 2024. This significant leadership change comes as Sanofi grapples with recent setbacks in its clinical pipeline.

Hudson, who took over as CEO in 2019, aimed to enhance Sanofi’s research capabilities and develop the company’s portfolio, particularly in immunology. His strategy included increased investments in research and development, especially as Sanofi prepares for the eventual loss of patent protection for its leading drug, Dupixent. This immunotherapy, co-marketed with Regeneron Pharmaceuticals, has been a cornerstone of Sanofi’s success and is expected to face patent expiration in the early 2030s.

Despite Hudson’s vision, the company encountered challenges that have raised concerns among investors. The board’s decision to change leadership reflects a desire to revitalize Sanofi’s approach to drug development, emphasizing the need for a fresh perspective amid ongoing clinical trials and market uncertainties.

Belén Garijo brings extensive experience to her new role, having led Merck KGgA since 2021. Her background in pharmaceuticals and biotechnology positions her as a strong candidate to guide Sanofi through its next phase of growth. The company aims to not only recover from recent setbacks but to also solidify its status as a leader in the global pharmaceutical industry.

As Garijo prepares to take the helm, stakeholders are looking for renewed confidence in Sanofi’s strategic direction. The incoming CEO will need to address investor concerns while continuing to pursue innovative therapies that could enhance the company’s pipeline.

This leadership transition at Sanofi marks a pivotal moment for the company as it seeks to navigate a competitive landscape and reinforce its commitment to advancing healthcare solutions.